TB-500 Side Effects and Safety: What Is Actually Known

Written by Dr. Andrii Kaleniuk. Updated November 5, 2026.

TB-500 has never been tested in humans: the only human safety data come from trials of full-length thymosin beta-4, which reported mild or moderate side effects and no serious ones in small studies, and the FDA's May 2026 evaluation found no human studies or toxicology data for TB-500 itself and flagged a possible risk of immune reactions. TB-500 is a short lab-made peptide (a seven-amino-acid protein fragment) based on part of thymosin beta-4, a natural repair protein, and the FDA says the two are not the same substance. Beyond the missing data, the known concerns are theoretical or indirect: laboratory and tumor-tissue studies link high thymosin beta-4 levels to cancer growth and spread, grey-market vials often fail purity and identity tests, injecting an unregulated product carries infection risk, and the substance is banned in sport. The side effects listed on many websites, such as headaches and tiredness, come from anecdotes, not studies. This guide separates what is measured from what is guessed, as of November 2026.

No. Thymosin beta-4 is a 43-amino-acid protein made naturally in the body, where it helps cells move and is involved in wound healing and blood vessel formation. TB-500 is a synthetic copy of a small section of it (amino acids 17 to 23, with an acetyl group added at one end). In its May 2026 evaluation for an advisory committee, the FDA wrote that 'thymosin beta-4 and TB-500 are not the same substance.' That matters because almost all of the human safety data people quote for TB-500 actually come from the full protein. See our introduction to TB-500 for background.

Whether TB-500 is safe is not known, because it has not been studied in people. The FDA searched the literature and stated that 'no articles were found in which TB-500 was administered to humans' and that 'nonclinical toxicological studies are not available.' Its conclusion was that 'potential safety risks associated with the use of TB-500 in humans are unknown.' The agency's adverse event database (FAERS) had zero reports for TB-500, and its food complaint system had two cases involving a TB-500 and BPC-157 blend, with no safety assessment possible. Zero reports does not mean zero harm, because most TB-500 is bought outside the medical system.

Several small, company-sponsored trials tested full-length thymosin beta-4 by injection, eye drops or skin gel. None tested TB-500. They used pharmaceutical-grade product under medical supervision, unlike a vial bought online.

In the Chinese IV trial, the side effects recorded included lab-value changes, ECG changes, vein irritation (phlebitis) and bruising at the needle site. A tumor blood marker (squamous cell carcinoma antigen) rose briefly in both drug and placebo groups. A few blood samples showed antibodies against the protein (1 of 108 single-dose and 2 of 56 multiple-dose samples), and these disappeared. Short, small trials like these cannot detect rare or long-term harms.

Many websites list headaches, tiredness or lethargy, nausea, flushing and injection-site redness as 'common' TB-500 side effects. We could not find a single study or credible case series behind these lists; they appear on vendor and symptom-checker pages without citations, and several of those pages cite references about thymosin beta-4 rather than TB-500. So 'TB-500 headaches' should be read as anecdotal reports, not documented effects. Anecdotes cannot show how often something happens or whether TB-500, rather than a contaminant, caused it. The closest real data are the IV thymosin beta-4 trials above, where vein irritation and needle-site bruising were recorded. If you are comparing peptides, our article on BPC-157 side effects runs into the same lack of human evidence.

There is no human evidence that TB-500 causes cancer, but there is a biological reason for concern that has not been ruled out. Thymosin beta-4 promotes cell movement and the growth of new blood vessels (angiogenesis), which is useful for wound healing (Journal of Investigative Dermatology, 1999) but is also how tumors grow and spread. Several lines of research link it to cancer:

These are associations in cells, animals and tumor tissue, not tests of TB-500 in people, and they do not show that taking TB-500 starts a cancer. The main concern is helping an existing, undetected tumor grow. Sport Integrity Australia states there is 'serious concern that it increases the spread and growth of cancer cells.' The same question for the other popular repair peptide is covered in does BPC-157 cause cancer.

Immunogenicity means the chance that a substance makes the immune system react to it, for example by forming antibodies or causing allergic-type reactions. The FDA's 2026 evaluation said TB-500 'may pose a significant risk for immunogenicity, potentially amplified by aggregation', meaning peptide molecules clumping together, which can make them look more foreign to the immune system. Reactions to impurities could not be ruled out either. This is a theoretical assessment, not an observed pattern, because no one has studied it in humans.

Often not very. A 2026 preprint (a study posted before peer review) by Mendias and Awan analysed independent lab tests of peptides from 203 synthesis companies collected between December 2024 and April 2026. TB-500 had the lowest median purity of any peptide tested, 97.29%, and the highest identity failure rate: 10.0% of samples did not contain the stated compound. Only 22.5% met the authors' compounding-grade criteria and 7.5% met manufactured-grade criteria. Across all peptides, bacterial endotoxin, a fever-causing contaminant from bacteria, was measurable in 15% of 243 tested samples, although there were no TB-500-specific endotoxin figures. Treat the exact numbers with caution, but what is in the vial may not match the label.

Most TB-500 is sold as a powder labelled 'for research use only' and injected under the skin. In a March 2026 warning letter to a peptide seller (about retatrutide and tirzepatide, not TB-500), the FDA noted that injected products 'bypass some of the body's key defenses against toxins and microorganisms' and that 'research use only' labelling does not change a product's legal status as a drug. In August 2026 the FDA sent five more warning letters to research-peptide sellers on unapproved-drug grounds. We found no FDA warning letter that names TB-500 specifically. Non-sterile products can cause skin infections, abscesses and reactions to contaminants. Combining it with BPC-157 adds a second unstudied substance; see the Wolverine stack.

Two events in 2026 caused confusion. On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with 1 abstention, in favour of adding TB-500 to the list of substances pharmacies may compound, even though FDA scientists had recommended against it because of the missing safety data. Then, on October 28, 2026, the Department of Health and Human Services (HHS) announced an interim enforcement-discretion policy for six peptides, including TB-500 and BPC-157. Regulators will, for now, not act against compounding pharmacies, federal facilities and physicians that meet conditions such as an FDA-registered source with a certificate of analysis and MedWatch reporting of serious side effects. It is not an approval, does not cover research-chemical sellers, and is not a finding that TB-500 is safe. Public comments are due around November 13, 2026, and HHS said it may revisit the policy if a safety signal appears. Our article on whether BPC-157 is legal covers the same policy from the BPC-157 side.

TB-500 falls under the World Anti-Doping Agency's S2 category (peptide hormones and growth factors) and is banned at all times, in and out of competition; Sport Integrity Australia says no therapeutic use exemption is available for any condition. Sanctions have followed without positive tests: in 2025, USADA gave triathlete Anthony McCauley a four-year ban for possession and use of BPC-157 and TB-500 after a whistleblower report, and New Zealand's Sports Tribunal banned an athlete for three years for trafficking TB-500 and other peptides. If you compete in a tested sport, any recovery benefit, discussed in TB-500 for muscle recovery, comes with a real risk to your eligibility.

If you are considering TB-500 for an injury, the most useful conversation is about the injury itself and treatments with evidence behind them. Be honest about what you have used.

For how TB-500 compares with the other commonly discussed repair peptide, see BPC-157 vs TB-500.

TB-500 side effects in humans are essentially unknown because the peptide has never been studied in people. The reassuring safety data people cite belong to full-length thymosin beta-4, a different molecule tested in small, short, company-sponsored trials. The FDA's 2026 review found no human or toxicology data for TB-500 and raised a possible immune-reaction risk; laboratory research links thymosin beta-4 to tumor growth; grey-market products often fail purity and identity tests; and the substance is banned in sport. The October 2026 HHS policy relaxes some enforcement but is not evidence of safety.

This article summarizes published research and regulatory documents for general information and is not medical advice. The human thymosin beta-4 trials cited were sponsored by the companies developing the drug, and none tested TB-500.